BRNS
Barinthus Biotherapeutics
BRNS • NASDAQ
Barinthus Biotherapeutics is a pharmaceutical preparations company trading on NASDAQ, led by CEO William James Enright.
CEOWilliam James Enright
Next Earnings
Upcoming earnings announcement for Barinthus Biotherapeutics
Date
Wednesday, May 6, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.31
Earnings History
Past 12 earnings reports for Barinthus Biotherapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | Q4 2025 | -$0.27Est: -$0.37 | +27.0% | - | — |  10-K |
| Nov 7, 2025 | Q3 2025 | -$0.36Est: -$0.42 | +14.3% | $15.0M | — | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.52Est: -$0.31 | -67.7% | - | — | 10-Q |
| May 7, 2025 | Q1 2025 | -$0.49Est: -$0.36 | -36.1% | - | — | 10-Q |
| Mar 20, 2025 | Q4 2024 | -$0.51Est: -$0.46 | -10.9% | - | — | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.21Est: -$0.44 | +52.3% | $15.0M | — | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.43Est: -$0.41 | -4.9% | - | — | 10-Q |
| May 13, 2024 | Q1 2024 | -$0.40Est: -$0.54 | +25.9% | -Est: $130.0K | -100.0% | 10-Q |
| Mar 20, 2024 | Q4 2023 | -$0.45Est: -$0.50 | +10.0% | -Est: $130.0K | -100.0% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.37Est: -$0.53 | +30.2% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.62Est: -$0.55 | -12.7% | $334.0KEst: $600.0K | -44.3% | 10-Q |
| May 12, 2023 | Q1 2023 | -$0.48Est: -$0.50 | +4.0% | $468.0KEst: $1.5M | -68.8% | — |